Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  inotuzumab ozogamicin
Find trials that include:  Any drugs shown
Results 1-7 of 7 for your search:
Start Over
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults with Newly Diagnosed B Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 39
Trial IDs: A041501, NCI-2016-01981, NCT03150693
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Older Patients with Previously Untreated Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 60 and over
Trial IDs: 2010-0991, NCI-2011-01123, NCT01371630
Inotuzumab Ozogamicin, Fludarabine Phosphate, Bendamustine Hydrochloride, and Rituximab before Donor Stem Cell Transplant in Treating Patients with Lymphoid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: 2012-0265, NCI-2012-02072, NCT01664910
Bosutinib and Inotuzumab Ozogamicin in Treating Patients with Recurrent or Refractory Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0435, NCI-2014-02606, NCT02311998
Inotuzumab Ozogamicin in Treating Patients with Acute Lymphocytic Leukemia after Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 16 to 75
Trial IDs: CASE1916, NCI-2017-00826, NCT03104491
Inotuzumab Ozogamicin in Treating Younger Patients with Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 1 to 21
Trial IDs: AALL1621, NCI-2016-01494, NCT02981628
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients with Relapsed or Refractory Acute Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1312, NCI-2013-01368, NCT01925131
Start Over